ClinicalTrials.gg
WithdrawnNCT05678205Updated Jul 30, 2025

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

A Phase 1/2 interventional study of AB-201 and Cyclophosphamide in Breast Cancer, Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Artiva Biotherapeutics, Inc.. Withdrawn at 2 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Artiva Biotherapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

Why this study was withdrawn
Corporate business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors. The primary objective of Phase 2 is to evaluate the efficacy of AB-201.

Subjects will receive up to 3 doses of AB-201, followed by scheduled assessments of overall health and tumor response.

02

Conditions studied

  • Breast Cancer
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

Artiva Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status 0 to 1.
  • confirmed expressed breast or gastric/GEJ cancer IHC ≥ 2+ within 6 months prior to study entry.
  • Confirmed diagnosis of an advanced/unresectable or HER2+ breast or gastric/GEJ cancer that is to, or intolerable of standard treatment, or for which no standard treatment is available.
  • Must have received prior cancer therapy: Subjects with breast cancer must have received ≥ 2 prior systemic therapies; subjects with gastric/GEJ cancer must have received ≥ 1 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy.

Exclusion criteria

Exclusion Criteria:

  • Known past or current other than inclusion diagnosis.
  • Known cardiac disease.
  • Active central nervous system (CNS) , or involvement of the CNS, unless there is a history of at least 3 months of sustained remission.
  • Unresolved toxicities from prior anticancer therapy.
  • Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy.
  • History of sensitivity or intolerance to cyclophosphamide or fludarabine.
  • Pregnant or lactating females and subjects of both sexes who are not willing to practice from the time of consent through 6 months after administration of the last AB-201 dose.
  • Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase 1 Dose Confirmation

    Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression

    Drug: AB-201 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 2 Cohort A

    AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC ≥2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available

    Drug: AB-201 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 2 Cohort B

    AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) that is relapsed to, refractory to, or intolerant of previous trastuzumab deruxtecan (T-DXd) based therapy

    Drug: AB-201 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 2 Cohort C

    AB-201 given to patients with advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression (IHC ≥ 2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available

    Drug: AB-201 · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

06

What researchers measure

Primary outcomes

  1. Safety: incidence and severity of adverse events and serious adverse events

    Time frame: From the time of consent through End of Study (up to 18 months per patient)

  2. Determination of Recommended Phase 2 Dose (RP2D): safety, preliminary efficacy (based on objective response rate (ORR) defined as the proportion of patients with a complete or partial response) and pharmacokinetics

    Time frame: From the time of consent through End of Study (up to 18 months per patient)

  3. Efficacy: Objective Response Rate, defined as the proportion of patients with a complete or partial response

    Time frame: From the time of consent through End of Study (up to 18 months per patient)

07

Study locations

2 sites
  • Oregon Health Science University (OHSU)
    Portland, Oregon 97239, United States
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Gyeonggi-do 16247, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2023; primary completion for Apr 2027, 44 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2022
First posted
Jan 10, 2023
StartEst.
Aug 1, 2023
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05678205
Lead sponsor
Artiva Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 30, 2025

Study contacts

Thorsten Graef, MD, Ph.D
study director · Artiva Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anpocogin

Start the discussion